Home / Market News / $XTNT
benzinga Corporate Catalyst Impact 75/100 ● negative

Xtant Medical Hldgs Lowers FY2026 Sales Guidance from $101.000M-$105.000M to $99.000M-$103.000M vs $102.058M Est

Aug 11, 2026, 11:01 AM UTC · Primary ticker $XTNT

Xtant Medical Holdings has revised its sales guidance for fiscal year 2026 downwards. This reduction indicates a potentially weaker revenue outlook than previously anticipated, which could negatively impact investor sentiment and the company's stock price.

Xtant Medical Holdings (XTNT) has lowered its sales guidance for fiscal year 2026 from an initial range of $101.000 million-$105.000 million to a new range of $99.000 million-$103.000 million. This downward revision suggests that the company anticipates lower revenue generation than previously projected, falling below the analyst estimate of $102.058 million. This news is likely to be perceived negatively by the market, as it indicates a potential slowdown in growth or increased competitive pressures. Short-term, XTNT's stock price may experience downward pressure as investors react to the reduced outlook. Long-term, the implications depend on the underlying reasons for the guidance cut and the company's ability to meet or exceed the new, lower targets. For traders, this presents a risk of further declines if the market interprets the cut as a sign of deeper operational issues.

$XTNT negative Lowered sales guidance
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.